NewsWork Gets Underway On Scotland’s First Medical Cannabis Cultivation...

Work Gets Underway On Scotland’s First Medical Cannabis Cultivation and Production Facility


SCOTLAND’S first home-grown cannabis medicines could be in UK patients’ hands in early 2022 after work started on a new £15m cultivation and production facility in the Borders.

With the UK’s one million-plus medical cannabis users currently reliant on imports, home-grown and black market suppliers this marks a significant milestone.

Work has started on the new £15m cultivation and production facility.

Hilltop Leaf says it hopes to harvest the first crop from 120,000 sq ft facility – equivalent to the size of two football pitches – later this year.

CEO Hamish Clegg told BusinessCann: “The main brands in the UK are Canadian and Dutch and we now have the opportunity to become one of the UK’s first domestic cannabis brands.

“This is a significant moment for the UK medical cannabis industry. Our aim is to deliver medicines and support to UK patients and help reduce the country’s reliance on imports.”

Boosting Domestic UK Supply

Hilltop Leaf’s first products will come as oils, flowers and tinctures with a one to one ratio of THC to CBD and the desire to support patients needing treatments for pain, epilepsy and Multiple Sclerosis.

As well as Mr Clegg the leadership team includes father and son William and Neil Ewart, Chief Financial Officer Ed Browne and science lead Colin Newbould.

The facility is under construction in an undisclosed, secluded and secure location, with abundant water supplies and the ability to source renewable energy from an adjacent wind farm.

When complete it will encompass an holistic operation from cultivation through to processing, extraction, product formulation and production, all under the umbrella of EU-GMP certification.

The company is currently working with the Home Office on securing the required Schedule One and Schedule Two drug licence approvals for cultivating commercial high-THC cannabis.

With few licensed UK cannabis medicines currently available Hilltop is also in discussion with the MHRA to secure licences for the production of ‘specials’ medicines, which is the prescription pathway for the vast majority of UK patients.

Hilltop is close to completion £2m equity funding round following an initial £500,000 investment and anticipates raising a further £2m equity funding and up to £10m borrowing to complete and operate the project.

It has also secured the £690,000 capital investment from Government agency South of Scotland Enterprise.

Momentum Behind UK Medical Cultivation

Mr Clegg is Director at Hannam & Partners and has previously raised $6m for a similar medical cannabis project overseas. He was formerly employed as an oil analyst at Bank of America Merrill Lynch.

CEO Hamish Clegg.

The Ewarts have a wealth of experience in construction and engineering projects in the Borders. In his role as Chairman of Hilltop Mr Ewart (snr) is maintaining close relations with the local community. When complete the facility will employ around 50 people.

As it builds the business Hilltop says will look to invest into research and development. Additional advisors include high-profile medical cannabis figures Prof Mike Barnes and Hannah Deacon of the Maple Tree Consultancy.

The development will see Hilltop become the UK’s second largest medical cannabis producer following trailblazer GW Pharmaceuticals.

GW is one of the world’s leading medical cannabis companies with its home-grown cannabis going into its licensed drugs Sativex and Epidyolex. Its first cultivation facility was built over 20 years ago.

Its research operations are based in Kent and its growing facilities are owned and managed by British Sugar in Wissington, Norfolk consisting of almost two million sq ft of growing space – equivalent to 34 football pitches.

There are a number of other companies looking to cultivate cannabis for medicines. Earlier this week we reported on Northern Leaf’s facility in Jersey, Ananda Developments, Sativa Wellness and Bridge Farm are all moving forward with cultivation plans.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

British People Open To Using Medical Cannabis – Yet Majority Unaware They Can Access It On Prescription 

A NEW national survey of 4,000 people has highlighted the need to improve awareness of cannabis as a medicine.  Key...

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint the European industry will continue to grow, say the continent’s...

Chrystal Capital Acts As Exclusive Advisor To Change Agronomy On £9.6m Fundraise

CHRYSTAL Capital Partners LLP, is an entrepreneurial corporate finance and investment house with an established global network of Single...

European Cannabis Stocks Review: ‘End’ Of US Cannabis Bear Market Rallies European Stocks 

FOLLOWING last week’s rally there has seen something of a lull with little movement for European cannabis stocks. Last week’s...

Business of Cannabis Conference Returns to New York City on November 3rd

In this second summit, the most influential business leaders, investors and politicians gather to discuss social equity, policy and...

Curaleaf Takes Majority Stake And Forms Strategic Partnership With Germany’s Four 20 Pharma In €20m Deal

CURALEAF Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading U.S. provider of consumer products in cannabis, announced that Curaleaf International...

Must read

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint...

European Cannabis Stocks Review: ‘End’ Of US Cannabis Bear Market Rallies European Stocks 

FOLLOWING last week’s rally there has seen something of...

You might also likeRELATED
Recommended to you